|new hiv meds 4 drugs in one pill taken once a day..
Jan 22, 2009
Hi Dr Ben,
could you please tell me about this new 4 drugs in one pill, once a day... it sounds great.. when will it be out for general use ???
thank you so much for your time.. tim
Gilead aims to start trials in 2009 of a new four-drugs-in-one-pill product, combining all its anti-HIV drugs, the company told Bloomberg news service yesterday.
The `Quad` pill will combine tenofovir and emtricitabine (already marketed as a two-drug pill called Truvada) with a new antireretroviral drug now in phase III studies, called elvitegravir. This drug belongs to a new class of antiretroviral drugs called integrase inhibitors, and will be combined with another new drug, called GS9350, which boosts levels of elvitegravir.
Gilead hopes that if pre-licensing studies are successful, elvitegravir could receive a license for use in treatment-experienced patients in 2010.
However Gilead has its eye on the market for patients new to treatment, currently dominated by another of its combination pills Atripla (co-marketed with Bristol-Myers Squibb) which contains tenofovir, emtricitabine and efavirenz (Sustiva).
Efavirenz may be less suitable for African-American patients, said Gilead president John Milligan, because it is metabolised more slowly by people of African descent, leading to a higher risk of central nervous system side-effects.
Although elvitegravirs long-term side-effect profile is unknown, another integrase inhibitor called raltegravir has shown that it is well-tolerated in comparison to efavirenz, and just as effective at suppressing viral load. Raltegravir (Isentress), manufactured by Merck, is likely to receive US approval for first-line use during 2009.
Gileads hope is that a four-in-one combination pill, taken once a day, could have an edge over raltegravir, which must be dosed twice daily.
| Response from Dr. Young
hi Tim and thanks for your post.
The so-called quad pill is indeed in development by Gilead-- it is a combination of the potential new boosting drug (ie, the long awaited replacement for Norvir) with Gilead's new integrase inhibitor and the parts of Truvada.
There's quite a bit of clinical science and good outcomes that will be required before FDA approval-- at least 2-3 years in my back-of-the-envelope calculation. To what extent the new combination meets or exceeds the characteristics of current first-line options remains to be seen, but suffice to say that there is a lot of interest.
Get Email Notifications When This Forum Updates or Subscribe With RSS
This forum is designed for educational purposes only, and experts are not rendering medical, mental health, legal or other professional advice or services. If you have or suspect you may have a medical, mental health, legal or other problem that requires advice, consult your own caregiver, attorney or other qualified professional.
Experts appearing on this page are independent and are solely responsible for editing and fact-checking their material. Neither TheBody.com nor any advertiser is the publisher or speaker of posted visitors' questions or the experts' material.